Entrada Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare Conference
Rhea-AI Summary
Entrada Therapeutics (Nasdaq: TRDA) will present at the 44th Annual J.P. Morgan Healthcare Conference. Dipal Doshi, CEO, will deliver the company presentation on Wednesday, January 14, 2026 at 3:45 PM PT (6:45 PM ET). A live webcast will be available on Entrada’s Investor Relations site and will be archived for 30 days after the event.
Positive
- None.
Negative
- None.
News Market Reaction
On the day this news was published, TRDA declined 1.32%, reflecting a mild negative market reaction.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Market Reality Check
Peers on Argus
Peers showed mixed moves: TLSA +0.65%, EPRX +2.29%, while CCCC -6.03%, CGTX -5%, TNYA -3.38%, suggesting stock-specific factors rather than a unified sector move.
Historical Context
| Date | Event | Sentiment | Move | Catalyst |
|---|---|---|---|---|
| Dec 04 | Inducement grants | Neutral | +1.6% | Equity awards to new hires under 2025 Inducement Equity Plan. |
| Nov 06 | Earnings update | Neutral | +0.1% | Q3 2025 financial results and DMD pipeline timing updates. |
| Oct 28 | Investor conferences | Neutral | +0.6% | Participation in Jefferies and Evercore healthcare investor events. |
| Sep 05 | Community grants | Neutral | +1.3% | DREAMS grants of <b>$50,000</b> each to two nonprofits. |
| Sep 02 | Inducement grants | Neutral | -1.1% | RSU and option grants to seven new non-executive employees. |
Recent company and conference announcements have been followed by relatively small single-day price reactions, mostly modestly positive.
Over the last six months, Entrada reported Q3 2025 results with cash of $326.8M and runway into Q3 2027, while advancing multiple Duchenne programs. The company announced recurring inducement equity grants under Nasdaq Listing Rule 5635(c)(4) and community support via the DREAMS Grant Program. It also highlighted visibility at investor conferences in late 2025. Today’s J.P. Morgan Healthcare Conference presentation notice extends that pattern of investor-relations and visibility updates rather than introducing new financial or clinical data.
Regulatory & Risk Context
An effective Form S-3 shelf filed on 2025-11-06 allows Entrada to offer up to $400,000,000 in various securities, including a $150,000,000 ATM program, providing flexibility to raise capital for R&D and working capital when market conditions permit.
Market Pulse Summary
This announcement details Entrada’s upcoming presentation at the 44th Annual J.P. Morgan Healthcare Conference on January 14, 2026, with a webcast and 30-day replay. It continues a series of investor-relations and conference updates following Q3 2025 results and prior event appearances. Investors tracking the story may focus on any new strategic, pipeline, or financial commentary delivered at the conference relative to previously disclosed cash of $326.8M and runway into Q3 2027.
AI-generated analysis. Not financial advice.
BOSTON, Dec. 17, 2025 (GLOBE NEWSWIRE) -- Entrada Therapeutics, Inc. (Nasdaq: TRDA) today announced that Dipal Doshi, Chief Executive Officer, will deliver a company presentation at the 44th Annual J.P. Morgan Healthcare Conference on Wednesday, January 14, 2026, at 3:45 PM PT (6:45 PM ET).
A live webcast will be available on the Presentations portion of Entrada’s Investor Relations website at https://ir.entradatx.com. The webcast will be archived and available for replay for 30 days after the event.
About Entrada Therapeutics
Entrada Therapeutics is a clinical-stage biopharmaceutical company aiming to transform the lives of patients by establishing a new class of medicines that engage intracellular targets that have long been considered inaccessible. The Company’s Endosomal Escape Vehicle (EEV™)-therapeutics are designed to enable the efficient intracellular delivery of a wide range of therapeutics into a variety of organs and tissues, resulting in an improved therapeutic index. Through this proprietary, versatile and modular approach, Entrada is advancing a robust development portfolio of RNA- and protein-based programs for the potential treatment of neuromuscular and ocular diseases, among others. The Company’s lead oligonucleotide programs are in development for the potential treatment of people living with Duchenne who are exon 44, 45, 50 and 51 skipping amenable. Entrada has partnered to develop a clinical-stage program, VX-670, for myotonic dystrophy type 1.
For more information about Entrada, please visit our website, www.entradatx.com, and follow us on LinkedIn.
Investor Contact
Karla MacDonald
Chief Corporate Affairs Officer
kmacdonald@entradatx.com
Media Contact
Megan Prock McGrath
CTD Comms, LLC
megan@ctdcomms.com
FAQ
When will Entrada Therapeutics (TRDA) present at the J.P. Morgan Healthcare Conference?
Who is presenting for Entrada Therapeutics (TRDA) at the January 2026 J.P. Morgan conference?
How can investors watch Entrada Therapeutics (TRDA) presentation on January 14, 2026?
Will the Entrada Therapeutics (TRDA) webcast be available after the J.P. Morgan presentation?
Where on Entrada’s site can I find the January 14, 2026 presentation webcast?
